Cargando…
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are available for advanced or metastatic disease. In the last decade, a better understanding of the molecular events involved in the tumori...
Autores principales: | Stjepanovic, Neda, Capdevila, Jaume |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990290/ https://www.ncbi.nlm.nih.gov/pubmed/24748771 http://dx.doi.org/10.2147/BTT.S39381 |
Ejemplares similares
-
Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
por: Zafón, Carles, et al.
Publicado: (2022) -
Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022) -
Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
por: Berciano‐Guerrero, Miguel‐Ángel
Publicado: (2022) -
Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019) -
Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer
por: Sambo, Marcel
Publicado: (2022)